Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03868254 · ClinicalTrials.gov registry record

Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)

A clinical trial of Glaucoma, sponsored by Allergan.

Completed
Registry status
174
Enrollment target
1
Study location

NCT03868254 is a study of Glaucoma that has completed, run by Allergan. The registered enrollment target is 174 participants, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03868254, a study of Glaucoma, has completed, sponsored by Allergan.

COMPLETED
Registry status
174 participants
Enrollment target
1
Study location

Study Summary

A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with phacoemulsification from 1 January 2014 to 1 October 2015.

Conditions Studied

Glaucoma

Interventions

  • PROCEDURE Phacoemulsification
  • DEVICE XEN Group

Study Locations (1)

California

  • Clinical Trials Registry Team - Irvine

Trial Details

FieldValue
Enrollment Target 174 participants
Start Date 2019-04-05
Est. Completion 2019-10-25

Sponsor

Allergan

314 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03868254

The ClinicalTrials.gov registry entry for NCT03868254 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 909-participant average among 92 other Glaucoma trials with a reported enrollment target (81% lower). The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Phacoemulsification is the first listed.

NCT03868254 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT03868254 about?

NCT03868254 is a clinical study titled "Chart Review of XEN 45 Gel Stent: Long Term Performance and Safety Assessment (XEN LT)". A retrospective, non-interventional, observational, multi-center, chart review study to be conducted in participants who underwent placement of the XEN 45 Gel Stent as a standalone procedure or in combination with phacoemulsification from 1 January 2014 to 1 October 2015.

What is the current status of trial NCT03868254?

This trial is currently completed. The enrollment target is 174 participants. The study started on 2019-04-05. Estimated completion is 2019-10-25.

What conditions does trial NCT03868254 study?

This clinical trial studies the following conditions: Glaucoma.

What interventions are being tested in trial NCT03868254?

The interventions under investigation include: Phacoemulsification (PROCEDURE), XEN Group (DEVICE).

Who is sponsoring clinical trial NCT03868254?

This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03868254 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Glaucoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Glaucoma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.